MedTrace Logo

COVID-19 Rapid Testing for Self-Administration Among an Asymptomatic Sample

NCT04896710 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 569

Last updated 2021-06-02

No results posted yet for this study

Summary

Point-of-care testing can provide an additional layer of protection to reduce transmission of COVID-19 safely and effectively in the population, and if such tests can be self-administered, barriers to access may be reduced. The investigators will conduct a study among those self-identifying as asymptomatic for COVID-19 to evaluate the reliability and feasibility of self-administration of a point-of-care nasal swab test, determine the sensitivity and specificity of the point-of-care nasal swab test relative to reverse transciptase polymerase chain reaction (RT-PCR) testing, and gather quantitative and qualitative data on the acceptability and self efficacy of self-administration.

Conditions

  • Covid19
  • Asymptomatic Shedding Viral

Interventions

DEVICE

SD Biosensor

Nasal swab SD biosensor to be self administered

Sponsors & Collaborators

  • Health Canada

    collaborator OTHER_GOV

  • Roche Pharma AG

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Sabrina T Wong, RN, PhD · University of British Columbia

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-26
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04896710 on ClinicalTrials.gov